Squarepoint’s Exagen XGN Stock Holding History

Squarepoint’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$507K	Sell	108,993 -179,832	-62%	-$677K	﹤0.01%	3420
2026 Q1	$866K	Buy	288,825 +200,793	+228%	+$777K	﹤0.01%	2905
2025 Q4	$535K	Buy	+88,032	New	+$801K	﹤0.01%	3157
2021 Q1	–	Sell	-10,078	Closed	-$133K	–	3682
2020 Q4	$133K	Sell	10,078 -7,774	-44%	-$110K	﹤0.01%	2650
2020 Q3	$194K	Buy	17,852 +3,997	+29%	+$51.5K	﹤0.01%	2104
2020 Q2	$172K	Sell	13,855 -2,318	-14%	-$31.4K	﹤0.01%	1869
2020 Q1	$258K	Buy	16,173 +909	+6%	+$18K	0.01%	1367
2019 Q4	$388K	Buy	+15,264	New	+$272K	﹤0.01%	1905

Other funds holding XGN

Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return

NCNMGF

Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FCM

FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

MBAM

Mink Brook Asset Management West Palm Beach, Florida $227M AUM 64.76% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Squarepoint's XGN Position: Q2 2026 in Review

Squarepoint reduced its Exagen (XGN) stake by 62% in Q2 2026, selling an estimated $677K and leaving 108,993 shares worth $507K. The position accounts for ﹤0.01% of the portfolio, ranked #3420.

Squarepoint first reported a position in XGN in Q4 2019 and has held it in 8 quarters since. The position peaked at $866K in Q1 2026. 57 funds tracked by Wall St. Rank hold XGN as of Q2 2026.

Squarepoint held 108,993 shares of Exagen worth $507K as of Q2 2026.
Squarepoint sold 179,832 Exagen shares in Q2 2026, an estimated $677K.
Exagen made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3420 holding.
Squarepoint first reported a position in Exagen in Q4 2019 and has held it in 8 quarters since.
Squarepoint's Exagen position peaked at $866K in Q1 2026.
57 funds tracked by Wall St. Rank held Exagen as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.